Ovarian cancer is the leading cause of death from gynecologic cancer in women worldwide. According to the National Cancer Institute, ovarian cancer has the highest mortality rate among all the reproductive cancers in women. Advanced stage diagnosis and chemo/radio-resistance is a major obstacle in treating advanced ovarian cancer. The most commonly employed chemotherapeutic drug for ovarian cancer treatment is cis-platin. As with most chemotherapeutic drugs, many patients eventually become resistant to cis-platin and therefore, diminishing its effect. The efficacy of current treatments may be improved by increasing the sensitivity of cancer cells to chemo/radiation therapies.
This study is focused on identifying the differential expression of regulatory microRNAs (miRNAs) between cis-platin sensitive (A2780), and cis-platin resistant (A2780/CP70) cell lines. Cell proliferation assays were conducted to test the sensitivity of the two cell lines to cis-platin.
Differential expression pattern analysis reveales changes in expression of 11 miRNAs out of 1,500 miRNAs analyzed. Out of the 11 miRNAs identified, 5 were up-regulated in the A2780/CP70 cell line and [click to continue…]
Incoming search terms for this article:
- microRNA cancer resistance
- miRNA CANCER RESISTANCE
- Published News Upcoming News Submit a New Story Groups radio advertising
- Published News Upcoming News Submit a New Story Groups university of pittsburgh school of medicine
- Published News Upcoming News Submit a New Story Groups advertising on the radio
- Published News Upcoming News Submit a New Story Groups npr national public radio
- Published News Upcoming News Submit a New Story Groups radio broadcast
- Published News Upcoming News Submit a New Story Groups drug rehabilitation
- Published News Upcoming News Submit a New Story Groups radio broadcast jobs
- Published News Upcoming News Submit a New Story Groups state government
{ 0 comments }




